Believers in the Extraordinary | Karyopharm
Karyopharm Therapeutics is a commercial-stage pharmaceutical company whose core technology centers on inhibition of nuclear export—specifically XPO1—as a mechanism to treat cancer. The company's lead approved medicine, selinexor (XPOVIO), is indicated for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma, and Karyopharm continues to develop its pipeline across additional blood cancers and solid tumors.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2013
Jul 2013
May 2013
Nov 2011
Jan 2011
Nov 2010
Create a free account to see which investors have funded this company.
Create Free Account
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...
Research-based development stage biopharmaceutical company that discovers and develops innovative...
Clinical-stage biopharmaceutical company developing T cell receptor-based adoptive cell therapies...
